1 Biotech Stock Investors Are Searching For

Before you go, we thought you'd like these...
Before you go close icon

The following video is from Friday's Motley Fool Money weekly roundtable discussion with host Chris Hill, as well as analysts Ron Gross, Charly Travers, and Joe Magyer.

In this segment, Google's annual Zeitgeist report included the top 10 "most Googled stocks of 2012." Charly shares why Arena Pharmaceuticals breakthrough drug and stock performance has investors searching for shares.


When it comes to do-or-die business, the biotech industry takes the cake. Arena Pharmaceuticals is one recent success story in the industry after gaining FDA approval for its innovative obesity drug. While the future looks bright for Arena, there are still plenty of obstacles ahead. In our brand new premium research report on Arena Pharmaceuticals, we walk investors through the must-know opportunities and threats facing the company. Since key news can develop quickly, we're also including a full year of updates for those who sign up. Click here now to learn more.

The article 1 Biotech Stock Investors Are Searching For originally appeared on Fool.com.

Chris Hill has no positions in the stocks mentioned above. The Motley Fool owns shares of Facebook and Google and has the following options: long JAN 2014 $20.00 calls on Facebook. Motley Fool newsletter services recommend Facebook and Google. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners